Laurent Fischer

Laurent Fischer

Senior Vice President, Head Liver Therapeutic Area at Allergan , Inc.

Clonshaugh Business and Technology Park Coolock, Dublin, Ireland

General Information


President and Chief Executive Officer  - Ocera Therapeutics Inc

President and Chief Operating Officer  - RxCentric Inc.

Chief Executive Officer  - Tobira Therapeutics Inc


M.D.  - University of Geneva , Switzerland

M.D.  - Medicine , Geneva Medical School

undergraduate degree  - University of Geneva , Switzerland

undergraduate degree  - University of Geneva and Geneva Medical School


BOARD OF ADVISORS Member  - Poïesis Therapeutics Inc

Chief Executive Officer and President  - Jennerex , Inc.

Board Member  - AIDS Healthcare Foundation Limited

Industry Co-chair of the Steering Committee  - Liver Therapeutic Area

Board Member  - Panacos Pharmaceuticals , Inc.

Advisory Board Member  - ALM

Chair of Board of Directors  - AHF

Member  - Forum for Collaborative HIV Research

Recent News  

Laurent Fischer
Senior Vice President & Liver Therapeutics Area Head Allergan Laurent Fischer is the Senior Vice President and Liver Therapeutic Head at Allergan. Laurent was the CEO of Tobira Therapeutics, which was recently acquired by Allergan. Laurent has also held postions of responsibility at Jennerex Biotherapeutics, Ocera Therapeutics, Telomedix, Auxeris Therapeutics, MedVantX, DuPont Pharmaceuticals and Roche.

Read More

Laurent Fischer, M.D.
Senior Advisor Laurent is a Senior Advisor on the Frazier Life Sciences team and has over 20 years of drug development and commercialization experience in the biopharmaceutical industry. Laurent joined Frazier Healthcare Partners' Life Sciences team as a Senior Advisor in March 2017. He was previously CEO of Frazier portfolio company Tobira Therapeutics, which was acquired by Allergan for up to $1.7 billion in 2016. He is currently Senior Vice President and Head of the Liver Therapeutic Area at Allergan. Prior to Tobira, Laurent was chairman and CEO of Jennerex, Inc., a company with a first-in-class oncolytic immunotherapy for Liver Cancer acquired for $150 million by Sillajen. Prior to Jennerex, he was co-founder, president and CEO of Ocera Therapeutics. Laurent has also held senior positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology. He launched Sustiva®, the first once-daily anti-HIV and 10th top prescribed specialty drug in 2015, and was involved in the launch of the first protease inhibitor in the United States. Laurent received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

Read More

Deborah Dunsire, CEO, Southern Cross Biotech; Laurent Fischer, SVP, Allergan; Ken Horne, CEO, Symic Bio; Jeremy Levin, Chairman & CEO, Ovid Therapeutics; Francois Nader, Chairman, Acceleron Pharma; Rob Perez, Partner, Vineyard Sound Advisors

Read More

Browse ZoomInfo’s Directories